Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 738.76% | -58.40% | 27.23% | 53.95% | 48.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 738.76% | -58.40% | 27.23% | 53.95% | 48.32% |
| Cost of Revenue | 10.95% | 26.06% | 37.34% | 42.99% | 47.51% |
| Gross Profit | 269.20% | -67.05% | -40.42% | -39.41% | -47.20% |
| SG&A Expenses | 57.00% | 17.86% | 21.62% | 14.80% | 8.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.49% | 24.81% | 34.83% | 38.15% | 40.29% |
| Operating Income | 208.39% | -56.72% | -36.69% | -34.10% | -37.96% |
| Income Before Tax | 226.31% | -65.46% | -41.45% | -36.42% | -38.09% |
| Income Tax Expenses | 1,636.33% | -131.88% | 322.22% | 181.48% | 193.13% |
| Earnings from Continuing Operations | 220.46% | -64.65% | -41.69% | -36.62% | -38.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 220.46% | -64.65% | -41.69% | -36.62% | -38.32% |
| EBIT | 208.39% | -56.72% | -36.69% | -34.10% | -37.96% |
| EBITDA | 214.81% | -58.93% | -38.21% | -35.37% | -39.14% |
| EPS Basic | 184.54% | -31.99% | -12.53% | -5.27% | -1.92% |
| Normalized Basic EPS | 188.85% | -32.61% | -12.31% | -5.12% | -1.75% |
| EPS Diluted | 177.78% | -32.11% | -12.64% | -5.38% | -2.02% |
| Normalized Diluted EPS | 182.10% | -32.61% | -12.31% | -5.12% | -1.75% |
| Average Basic Shares Outstanding | 29.63% | 25.66% | 25.60% | 29.14% | 34.85% |
| Average Diluted Shares Outstanding | 31.02% | 25.66% | 25.60% | 29.14% | 34.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |